A Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a (Lambda) Compared With Placebo in Outpatients With Mild COVID-19
Latest Information Update: 24 May 2021
At a glance
- Drugs Peginterferon lambda-1a (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms COVID-Lambda
- 19 May 2021 Status changed from active, no longer recruiting to completed.
- 28 Sep 2020 Results presented in an Eiger BioPharmaceuticals media release.
- 24 Sep 2020 Planned End Date changed from 31 May 2022 to 1 May 2021.
Most Recent Events
Trial Overview
Purpose
To evaluate the efficacy of a single dose of subcutaneous injections of 180 ug of Peginterferon Lambda-1a, compared with placebo in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with uncomplicated COVID-19 disease.
Primary Endpoints
Duration Until Viral Shedding Cessation
description: Time to first of two consecutive negative respiratory secretions obtained by oropharyngeal and/or anterior nare swabs for SARS-CoV-2 by qRT-PCR.
time_frame: Assessed for up to 28 days
Other Endpoints
Change in Sars-CoV-2 Viral Load
description: Log10 Oropharyngeal viral load over time, mean change at day 14 (SD). Sars-CoV-2 RNA level in oropharyngeal and/or anterior nare swabs collected daily.
time_frame: baseline, day 14
Area Under the Curve of SARS-COV-2 Viral Load
description: Log10 viral load area under the curve through day 14, median (IQR). Area under the curve of SARS-CoV-2 viral load in oropharyngeal and/or anterior nare swabs collected daily.
time_frame: baseline through day 14
Duration Until Resolution of Symptoms
description: Duration until resolution of symptoms in days, median (95% CI). Time to alleviation of all symptoms (fever, chills, cough, nasal congestion, muscle pains), defined as the time from initiation of treatment until all symptoms are rated as absent or mild in symptomatic patients.
time_frame: Up to 28 days
Count of Participants Requiring Emergency Department Visits or Hospitalizations Within 28 Days of Initiation of Treatment
time_frame: 28 days [1]
Diseases Treated
Indication | Qualifiers | Patient Segments |
---|---|---|
COVID 2019 infections | treatment | - |
Subjects
- Subject Type patients
-
Number
Planned: 120
Actual: 120
- Sex male & female
- Age Group 18-75 years; adult; elderly
Patient Inclusion Criteria
1. Age ≥ 18 years and ≤ 75 years at the time of the assessment 2. Able and willing to understand the study, adhere to all study procedures, and provide written informed consent 3. Diagnosis of COVID-19 disease: 1. If symptomatic, the presence of mild to moderate symptoms without signs of respiratory distress, with FDA-cleared molecular diagnostic assay positive for SARS-CoV-2 within 72 hours from swab to the time of commencing informed consent: 2. If asymptomatic, initial diagnosis of SARS-CoV-2 infection with positive FDA-cleared molecular diagnostic assay obtained no more than 72 hours from initial swab to the time of commencing informed consent
Patient Exclusion Criteria
1. Patients who are hospitalized for inpatient treatment or currently being evaluated for potential hospitalization at the time of initiation of informed consent 2. Patients with a known allergy to Peginterferon Lambda-1a or any component thereof 3. Display symptoms of respiratory distress (Respiratory rate >20, room air oxygen saturation of <94%.) 4. Participation in a clinical trial with or use of any investigational agent within 30 days before screening 5. Treatment with interferons (IFN) within 12 months before screening 6. Previous use of Peginterferon Lambda-1a 7. History or evidence of any intolerance or hypersensitivity to IFNs or other substances contained in the study medication. 8. Female patients who are pregnant or breastfeeding. Male patients must confirm that their female sexual partners are not pregnant. 9. Current or previous history of decompensated liver disease (Child-Pugh Class B or C) or hepatocellular carcinoma 10. Co-infected with human immunodeficiency virus (HIV) 11. Significant abnormal laboratory test results at screening. 12. Other significant medical condition that may require intervention during the study 13. Concurrent use of any of the following medications: 1. Therapy with an immunomodulatory agent 2. Current use of heparin or Coumadin 3. Received blood products within 30 days before study randomization 4. Use of hematologic growth factors within 30 days before study randomization 5. Systemic antibiotics, antifungals, or antivirals for treatment of active infection within 24 hours before study randomization 6. Any prescription or herbal product that is not approved by the investigator 7. Long-term treatment (> 2 weeks) with agents that have a high risk for nephrotoxicity or hepatotoxicity unless it is approved by the medical monitor 8. Receipt of systemic immunosuppressive therapy within 3 months before screening
Trial Details
Identifiers
Identifier | Owner |
---|---|
NCT04331899 | ClinicalTrials.gov: US National Institutes of Health |
55619 | - |
Organisations
- Affiliations Eiger BioPharmaceuticals
Trial Dates
-
Initiation Dates
Planned : 15 Apr 2020
Actual : 25 Apr 2020
-
Primary Completion Dates
Planned : 31 May 2021
Actual : 14 Aug 2020
-
End Dates
Planned : 01 May 2021
Actual : 06 May 2021
Other Details
- Design parallel; prospective; randomised; single-blind
- Phase of Trial Phase II
- Location USA
- Focus Therapeutic Use
Interventions
Drugs | Route | Formulation |
---|---|---|
Peginterferon lambda-1aPrimary Drug | Subcutaneous | Injection |
Study drug Peginterferon Lambda-1a
Study participants assigned to study drug will receive a single subcutaneous dose of Peginterferon Lambda-1a in addition to standard of care treatment.
Drug: Peginterferon Lambda-1a (Peginterferon Lambda-1a (180 ug subcutaneous injection) single dose along with Standard of Care)
Placebo injection
Study participants will receive a placebo along with the standard of care treatment.
Other: Placebo (Placebo subcutaneous injection along with Standard of Care Treatment for COVID-19 Infection)
Results
Therapeutic efficacy
In a phase II trial, treatment with peginterferon lambda-1a reported no difference in the duration of COVID-2019 viral shedding and time to symptom resolution when compared with placebo [2] .
Adverse events
In a phase II trial, treatment with peginterferon lambda-1a was well-tolerated in patients with COVID-2019 infections. Few adverse events were reported which included elevated transaminases which was self-resolved [2] .
Publications
-
Eiger BioPharmaceuticals, Inc. Eiger Announces Results of Investigator Sponsored Study in Outpatients with Mild and Uncomplicated COVID-19. Media-Rel 2020;.
Media Release
Trial Centres
Investigators
Investigator | Centre Name | Trial Centre Country |
---|---|---|
Julie Parsonnet
6507254561
show details
parsonnt@stanford.edu |
, Stanford University |
-
|
Prasanna Jagannathan
6507245343 prasj@stanford.edu
show details
|
Stanford University School of Medicine | USA |
Upinder Singh
6507234045 usingh@stanford.edu
show details
|
Professor (Medicine -Infectious Diseases) |
-
|
Centres
Centre Name | Location | Trial Centre Country |
---|---|---|
- |
-
|
-
|
Professor (Medicine -Infectious Diseases) |
-
|
-
|
Stanford University |
-
|
-
|
Stanford University School of Medicine | Stanford, California | USA |
Stanford University School of Medicine | Stanford, California | USA |
Trial History
Event Date | Event Type | Comment |
---|---|---|
24 May 2021 | Other trial event | Last checked against the ClinicalTrials.gov record. Updated 24 May 2021 |
19 May 2021 | Status change - completed | Status changed from active, no longer recruiting to completed. Updated 24 May 2021 |
28 Sep 2020 | Results | Results presented in an Eiger BioPharmaceuticals media release. Updated 30 Sep 2020 |
24 Sep 2020 | Completion date | Planned End Date changed from 31 May 2022 to 1 May 2021. Updated 07 Oct 2020 |
24 Sep 2020 | Status change - active, no longer recruiting | Status changed from recruiting to active, no longer recruiting. Updated 07 Oct 2020 |
30 Apr 2020 | Other trial event | According to an Eiger BioPharmaceuticals media release, the first patients have been dosed in this study at the Stanford University School of Medicine. Updated 05 May 2020 |
23 Apr 2020 | Status change - recruiting | Status changed from not yet recruiting to recruiting. Updated 29 Apr 2020 |
08 Apr 2020 | New trial record | New trial record Updated 08 Apr 2020 |
Table of Contents
References
-
ClinicalTrials.gov: US National Institutes of Health. Trial-Reg 2023;.
Available from: URL: http://clinicaltrials.gov -
Eiger BioPharmaceuticals, Inc. Eiger Announces Results of Investigator Sponsored Study in Outpatients with Mild and Uncomplicated COVID-19. Media-Rel 2020;.
Media Release -
Eiger BioPharmaceuticals. Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG